New hope for rare sugar disorder: experimental drug aims to slash dangerous lows
Disease control
Ongoing
This study tests an investigational drug called RZ358 in 56 people aged 3 months to 45 years with congenital hyperinsulinism, a rare condition causing dangerously low blood sugar. Participants receive RZ358 or a placebo added to their usual treatments for 24 weeks, followed by an…
Phase: PHASE3 • Sponsor: Rezolute • Aim: Disease control
Last updated May 17, 2026 09:22 UTC